224 related articles for article (PubMed ID: 17949071)
1. Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring.
Barreiro G; Guimarães CR; Tubert-Brohman I; Lyons TM; Tirado-Rives J; Jorgensen WL
J Chem Inf Model; 2007; 47(6):2416-28. PubMed ID: 17949071
[TBL] [Abstract][Full Text] [Related]
2. From docking false-positive to active anti-HIV agent.
Barreiro G; Kim JT; Guimarães CR; Bailey CM; Domaoal RA; Wang L; Anderson KS; Jorgensen WL
J Med Chem; 2007 Nov; 50(22):5324-9. PubMed ID: 17918923
[TBL] [Abstract][Full Text] [Related]
3. Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus.
Zhou Z; Liu T; Wu G; Kang D; Fu Z; Wang Z; De Clercq E; Pannecouque C; Zhan P; Liu X
Org Biomol Chem; 2019 Mar; 17(12):3202-3217. PubMed ID: 30839042
[TBL] [Abstract][Full Text] [Related]
4. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
5. Docking-MM-GB/SA and ADME screening of HIV-1 NNRTI inhibitor: nevirapine and its analogues.
Sengupta D; Verma D; Naik PK
In Silico Biol; 2008; 8(3-4):275-89. PubMed ID: 19032162
[TBL] [Abstract][Full Text] [Related]
6. A Triazinone Derivative Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.
Urano E; Miyauchi K; Kojima Y; Hamatake M; Ablan SD; Fudo S; Freed EO; Hoshino T; Komano J
ChemMedChem; 2016 Oct; 11(20):2320-2326. PubMed ID: 27634404
[TBL] [Abstract][Full Text] [Related]
7. Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Chen X; Liu X; Meng Q; Wang D; Liu H; De Clercq E; Pannecouque C; Balzarini J; Liu X
Bioorg Med Chem Lett; 2013 Dec; 23(24):6593-7. PubMed ID: 24239481
[TBL] [Abstract][Full Text] [Related]
8. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
[TBL] [Abstract][Full Text] [Related]
10. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Zeng ZS; He QQ; Liang YH; Feng XQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
Bioorg Med Chem; 2010 Jul; 18(14):5039-47. PubMed ID: 20598556
[TBL] [Abstract][Full Text] [Related]
11. Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
Fu Z; Zhang T; Zhou Z; Kang D; Sun L; Gao S; Cherukupalli S; De Clercq E; Pannecouque C; Liu X; Zhan P
Bioorg Med Chem; 2021 Jul; 42():116239. PubMed ID: 34090079
[TBL] [Abstract][Full Text] [Related]
12. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.
D'Cruz OJ; Uckun FM
J Enzyme Inhib Med Chem; 2006 Aug; 21(4):329-50. PubMed ID: 17059165
[TBL] [Abstract][Full Text] [Related]
13. Molecular Docking and Molecular Dynamics Simulation Based Approach to Explore the Dual Inhibitor Against HIV-1 Reverse Transcriptase and Integrase.
Chander S; Pandey RK; Penta A; Choudhary BS; Sharma M; Malik R; Prajapati VK; Murugesan S
Comb Chem High Throughput Screen; 2017; 20(8):734-746. PubMed ID: 28641512
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel inhibitors of HIV-1 reverse transcriptase through virtual screening of experimental and theoretical ensembles.
Ivetac A; Swift SE; Boyer PL; Diaz A; Naughton J; Young JA; Hughes SH; McCammon JA
Chem Biol Drug Des; 2014 May; 83(5):521-31. PubMed ID: 24405985
[TBL] [Abstract][Full Text] [Related]
15. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
Frey KM; Puleo DE; Spasov KA; Bollini M; Jorgensen WL; Anderson KS
J Med Chem; 2015 Mar; 58(6):2737-45. PubMed ID: 25700160
[TBL] [Abstract][Full Text] [Related]
16. Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors.
Xu S; Song S; Sun L; Gao P; Gao S; Ma Y; Kang D; Cheng Y; Zhang X; Cherukupalli S; De Clercq E; Pannecouque C; Liu X; Zhan P
Bioorg Med Chem; 2022 Jan; 53():116531. PubMed ID: 34890994
[TBL] [Abstract][Full Text] [Related]
17. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
18. Structural optimization of N
Monforte AM; De Luca L; Buemi MR; Agharbaoui FE; Pannecouque C; Ferro S
Bioorg Med Chem; 2018 Feb; 26(3):661-674. PubMed ID: 29291935
[TBL] [Abstract][Full Text] [Related]
19. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission.
D'Cruz OJ; Uckun FM
Curr HIV Res; 2006 Jul; 4(3):329-45. PubMed ID: 16842085
[TBL] [Abstract][Full Text] [Related]
20. Unbinding Dynamics of Non-Nucleoside Inhibitors from HIV-1 Reverse Transcriptase.
Dodda LS; Tirado-Rives J; Jorgensen WL
J Phys Chem B; 2019 Feb; 123(8):1741-1748. PubMed ID: 30571126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
